Prosecution Insights
Last updated: November 04, 2026
Application No. 18/692,560

MILVEXIAN FOR PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISORDERS

Non-Final OA §103
Filed
Mar 15, 2024
Priority
Sep 17, 2021 — provisional 63/245,522 +2 more
Examiner
SANCHEZ, JUSTIN CHRISTOPHER
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Jansssen Pharmaceutica NV
OA Round
1 (Non-Final)
87%
Grant Probability
Favorable
1-2
OA Rounds
8m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 87% — above average
87%
Career Allowance Rate
48 granted / 55 resolved
+27.3% vs TC avg
Moderate +12% lift
Without
With
+12.1%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
26 currently pending
Career history
86
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
31.8%
-8.2% vs TC avg
§102
18.5%
-21.5% vs TC avg
§112
35.8%
-4.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 55 resolved cases

Office Action

§103
DETAILED ACTION Claims 1, 5-7, 11, 23, 27, 29-34, 36 and 75-92, submitted 14 August 2026, are pending in the application. Claims 75-92 are new. Claims 2-4 and 15-20 have been canceled by the applicant. Claims 1, 5-7, 11, 23, 27, 29-34, 36 and 75-92 are subject to examination in the instant Office Action. Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant’s election of Group I, claims 1-7, 11, 23, 27, 29-34 and 36, in the reply filed on 14 August 2026 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.01(a)). Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or non-obviousness. Claims 1, 5-7, 11, 23, 27, 29-34, 36, and 75-92 are rejected under 35 U.S.C. 103 as being unpatentable over Garmise et al. (WO 2020/210629 A1) as evidenced by Mainbourg et al. ("Twice-or once-daily dosing of direct oral anticoagulants, a systematic review and meta-analysis." Thrombosis Research 197 (2021): 24-32.). Garmise teaches a method for the treatment and prevention of a thromboembolic disorder by orally administering compound (I) to a human patient in a dose preferably ranging from 100 to about 500 mg (paragraphs 25 and 72). Additionally, it’s taught that compound (I) has the same chemical structure as the milvexian of the instant application (paragraph 4). Therefore, Garmise teaches all of the limitations of instant claim 1. Consequently, claim 87 is also rejected as it recites the limitation “wherein the milvexian, or pharmaceutically acceptable salt thereof, is milvexian”. Claims 88 and 89 are also rejected for the above reasons as these claims recite the limitations “for preventing a venous thromboembolic disorder” and “for treating a venous thromboembolic disorder”, respectively. Claims 5-7 are rejected for the reasons above as they recite the limitation wherein the total daily dose is 100 mg, 150 mg, and 200 mg, respectively. These dosage amounts are encompassed by the range taught by Garmise in paragraph 72. Claim 11 recites the limitation wherein the venous thromboembolic disorder is proximal and/or distal deep vein thrombosis, nonfatal pulmonary embolism, or death. This claim is rejected as Garmise teaches wherein the thromboembolic disorder is selected from venous thrombosis, deep vein thrombosis, pulmonary embolism or ischemic sudden death (paragraphs 94-95). This reference does not explicitly recite wherein the venous thromboembolic disorder is proximal and/or distal deep vein thrombosis, however it would have been prima facie obvious for one skilled in the art to at least try to prevent or treat these specific types of venous thromboembolic disorders with milvexian through routine experimentation. Consequently, this also reads on the limitations of instant claims 78-80 which recite the limitations “wherein the venous thromboembolic disorder is proximal and/or distal deep vein thrombosis”, wherein the venous thromboembolic disorder is nonfatal pulmonary embolism” and “wherein the venous thromboembolic disorder is death”, respectively. Regarding claim 23, Garmise teaches a method for the treatment and prevention of a thromboembolic disorder by orally administering compound (I) to a human patient in a dose preferably ranging from 100 to about 500 mg (paragraphs 25 and 72). Garmise does not explicitly teach wherein “orally administering a total daily dose of 100 mg milvexian, or a pharmaceutically acceptable salt thereof once or twice daily”. However, it's known in the art, as evidenced by Mainbourg et al. that administration of anticoagulants in the treatment or prevention of thrombosis varies between once or twice daily according to molecule and indication chosen (pg. 25, Section “Introduction”, Left Col., 1st paragraph). Based on this fact, it can be assumed that the practitioner would administer the anticoagulant, milvexian, once or twice daily. Consequently, this also reads on the limitations of instant claims 34 and 83 which recites the limitations ”wherein milvexian is administered twice daily” and “wherein the milvexian, or pharmaceutically acceptable salt thereof, is administered once daily”, respectively. Garmise also does not explicitly state wherein “an incidence rate of total venous thromboembolism events in the human patient treated with the milvexian, or pharmaceutically acceptable salt thereof is less than 25%”. However, this is merely a result of the administration of milvexian at a daily dose of 100 mg. Garmise teaches the capsules containing the preferred range of about 100 to about 500 mg of milvexian in paragraph 72. With the lower range of 100 mg being identical to the claimed dose in the instant claim, it would follow that the human patient of Garmise would also teach an incidence rate of less than 25%. Therefore, Garmise teaches all of the limitations of instant claim 23. This also reads on the limitations of instant claim 82 which recites wherein the milvexian or pharmaceutically acceptable salt thereof is administered at a total daily dose ranging from 100 mg to 400 mg. Claim 90 is also rejected for the above reasons as it recites the limitation “wherein the milvexian, or pharmaceutically acceptable salt thereof, is milvexian”. Garmise teaches the chemical structure of compound (I) is identical to that of milvexian (paragraph 4). Claims 91 and 92 are also rejected for the above reasons as these claims recite the limitations “for preventing a venous thromboembolic disorder” and “for treating a venous thromboembolic disorder”, respectively. Claim 27 is rejected for the same reason as detailed above. Garmise teaches a dosage range which encompasses the claimed dosage amount. Therefore, it would follow that the incidence rate of total venous thromboembolic events would also be less than 20%. This same logic is applied to instant claims 29 which recites the limitation wherein the incidence rate of total venous thromboembolic events is less than 15%. Claim 81 is rejected for this same reason as it recites the limitation wherein the incidence rate of total venous thromboembolism events is less than 10%. Claims 30-33 are rejected for the reasons above as they recite the limitation wherein the total daily dose is 100 mg, 150 mg, 200 mg and 400 mg, respectively. These dosage amounts are encompassed by the range taught by Garmise in paragraph 72. Claim 36 is rejected on the basis that it does not add an additional step to the method described in independent claim 23 but instead recites an observed inherent feature as a result of the comparison study between milvexian and enoxaparin provided by the Applicant. As Garmise teaches all of the limitations of the independent claim from which claim 36 is dependent of, it would follow that this inherent feature is also present within the Garmise reference whether it was known at the time or not. Thus, the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977). See MPEP 2112(I). Claim 36 is rejected on the basis that it does not add an additional step to the method described in independent claim 23 but instead recites an observed inherent feature as a result of the comparison study between milvexian and enoxaparin provided by the Applicant. As Garmise teaches all of the limitations of the independent claim from which claim 36 is dependent, it would follow that this inherent feature is also present within the Garmise reference whether it was known at the time or not. Thus, the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977). See MPEP 2112(I). Regarding claim 75, while Garmise does not explicitly teach wherein the total daily dose is administered in a single dose, it can be reasoned that one skilled in the art would administer milvexian in a single dose or in two doses based on the teachings of Mainbourg which states that administration of anticoagulants in the treatment or prevention of thrombosis varies between once or twice daily according to molecule and indication chosen (pg. 25, Section “Introduction”, Left Col., 1st paragraph). Consequently, this also reads on the limitations of instant claims 76 and 77. Claim 84 is rejected because the recited limitation only narrows independent claim 23 to being “clinically proven effective”, while maintaining the limitation of less than 25% of the incidence rate of total venous thromboembolism events in a patient treated with milvexian between both claims. As with claim 23, this recitation is merely a result of the administration of milvexian at a daily dose of 100 mg. Garmise teaches the capsules containing the preferred range of about 100 to about 500 mg of milvexian in paragraph 72. With the lower range of 100 mg being identical to the claimed dose in the instant claim, it would follow that the human patient of Garmise would also reach an incidence rate of less than 25%. Claim 85 is rejected on the basis that, while Garmise does not teach wherein the total daily dose is administered as 50 mg of milvexian twice per day, it would have been prima facie obvious to one skilled in the art, as evidenced by the teachings of Mainbourg, to divide the total daily dose into two smaller equal dosages to maintain the continuity of drug action. Consequently, claim 86 is also rejected as the compound taught by Garmise is structurally identical to that of milvexian. Conclusion No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JUSTIN CHRISTOPHER SANCHEZ whose telephone number is (703)756-5336. The examiner can normally be reached Monday -Friday (0730-1700). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. JUSTIN CHRISTOPHER SANCHEZ Examiner Art Unit 1622 /J.C.S./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Mar 15, 2024
Application Filed
Oct 23, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778919
SMALL MOLECULE MELPHALAN HYDROGEL AND METHOD FOR PREPARING THE SAME
2y 3m to grant Granted Nov 03, 2026
Patent 12773461
A Camptothecin Drug and Its Antibody Conjugate Thereof
4y 3m to grant Granted Oct 27, 2026
Patent 12766125
TREATMENT AND PREVENTION OF INFECTIONS USING VEGETABLE OIL-DERIVED POLYOLS
1y 1m to grant Granted Oct 20, 2026
Patent 12746216
COMBINATORY TREATMENT
3y 11m to grant Granted Sep 29, 2026
Patent 12741976
QUINOXALINE DERIVATIVES AND USES THEREOF
3y 1m to grant Granted Sep 22, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
87%
Grant Probability
99%
With Interview (+12.1%)
3y 4m (~8m remaining)
Median Time to Grant
Low
PTA Risk
Based on 55 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month